Survival trends in head and neck cancer: Opportunities for improving outcomes

Oncologist

Volumn 15, Issue 9, 2010, Pages 921-923

  Rodriguez, Cristina P ^a   Adelstein, David J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; WART VIRUS VACCINE;

ALCOHOL CONSUMPTION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CIGARETTE SMOKING; COMORBIDITY; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; EDITORIAL; EUROPE; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RISK ASSESSMENT; SEXUAL BEHAVIOR; SMOKING CESSATION; SOCIAL ASPECT; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION; WART VIRUS;

HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; RISK FACTORS;

EID: 77957791940     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0237     Document Type: Editorial

References (13)

1. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. The Oncologist 2010;15: 994-1001.
2. Browman GP, Wong G, Hodson I et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993;328:159-163.
3. Fox JL, Rosenzweig KE, Ostroff JS. The effect of smoking status on survival following radiation therapy for non-small cell lung cancer. Lung Cancer 2004;44:287-293.
4. Videtic GM, Stitt LW, Dar AR et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21: 1544-1549.
5. Chaturvedi AK, Engels EA, Anderson WF et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619
6. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
7. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
8. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001;344:1125-1131.
9. Schwartz SR, Yueh B, McDougall JK et al. Human papillomavirus infection and survival in oral squamous cell cancer: A population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
10. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
11. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
12. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943.
13. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 2009;374: 301-314.